Hong Kong Laureate Forum: Calling Outstanding Young Scientists in Astronomy, Life Science and Medicine, and Mathematical Sciences!
14.9.2020 04:00:00 EEST | Business Wire | Press release
Open application for the inaugural Hong Kong Laureate Forum starts today and will end on 13 December 2020. We welcome undergraduates, postgraduates and PhD graduates who are aged 35 or below and studying or conducting research in Astronomy, Life Science and Medicine, Mathematical Sciences or other closely related subjects to apply for the Hong Kong Laureate Forum and become one of the 200 selected young scientists to be inspired by world-renowned Shaw Laureates. Eligible Young Scientists are welcome to complete and submit their applications via this link: https://hklaureateforum.org/en/application-form
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200913005003/en/
Open Application from 14 September to 13 December 2020 (Graphic: Business Wire)
The inaugural Hong Kong Laureate Forum will be held on 15-20 November 2021 in Hong Kong. Being Asia’s world city and a city long celebrated for its vibrancy, Hong Kong is an ideal place for such an international gathering.
During a week-long programme, there will be ample opportunities for exchanges between participating Shaw Laureates and the young scientists. Apart from plenary lectures, panel discussions and parallel group sessions conducted by Shaw Laureates and other distinguished scientists, the programme will also offer informal and cozy gatherings with plenty of chances of networking and dialogues. There will also be presentation sessions for selected young scientists to showcase their latest research ideas to spark intellectual exchanges.
Mrs DO PANG Wai Yee, Secretary-General of the Council of the Hong Kong Laureate Forum (the HKLF) said: “As of today, we have received positive response from over 20 Shaw Laureates, including several Nobel Laureates and Fields Medalist, to join our Forum.”
Professor Steven Balbus, Shaw Laureate in Astronomy 2013 remarked: “I have nothing but pleasant memories of Hong Kong and I look forward to many more. It’s a city that feels exciting and that things are working. I think the Hong Kong Laureate Forum is going to be extremely exciting and a very special program that’s going to capture the imagination of the public.”
Professor Simon White, Shaw Laureate in Astronomy 2017 said: “I think the significance of the Shaw Prize is because it makes certain aspects of science visible to a wider public. And this fuels the curiosity which leads people to do science, which pushes them to improve their capabilities. I hope the Hong Kong Laureate Forum will make young people really enthusiastic and curious about science.”
The most outstanding 200 young scientists will be selected to join the inaugural Forum by a Scientific Review Panel comprising local and non-local academics. All applicants, either successful or not, will receive email notification in April 2021.
For enquiries regarding application, please contact Forum Programmes and Participants Enquiry at programme@hklaureateforum.org.
Background
The Hong Kong Laureate Forum is an annual scientific exchange event organized by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by Lee Shau Kee Foundation. The important partner of the HKLF is The Shaw Prize Foundation which organizes the annual international award The Shaw Prize.
To the Press
With this press release, we would like to extend an invitation to the Press to attend and report on the inaugural Hong Kong Laureate Forum.
Website:
https://www.hklaureateforum.org
Facebook:
https://www.facebook.com/HKLaureateForum
Twitter:
https://www.twitter.com/HKLaureateForum
Weibo:
https://www.weibo.com/hklaureateforum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200913005003/en/
Contact information
Forum Programmes and Participants Enquiry
Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom